Meeting
2019 ASCO Annual Meeting
Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).
Authors
Dae Won Kim
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Dae Won Kim , Hanna Kelly Sanoff , Andrew Stewart Poklepovic , Fatima Tariq , Andrew B. Nixon , Yingmiao Liu , Richard D. Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02115542
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4083)
DOI
10.1200/JCO.2019.37.15_suppl.4083
Abstract #
4083
Poster Bd #
188
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
First Author: Richard D. Kim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.
First Author: Raed Moh'd Taiseer Al-Rajabi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim